Sarwar M.; Semenas J.; Miftakhova R.; Simoulis A.; Robinson B.; Wingren A.; Mongan N.; Heery D.; Johnsson H.; Abrahamsson P.; Dizeyi N.; Luo J.; Persson J.
(2016)
One mechanism of resistance of prostate cancer (PCa) to enzalutamide (MDV3100) treatment is the increased expression of AR variants lacking the ligand binding-domain, the best characterized of which is AR-V7. We have ...